This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (291) Drug Repurposing and Off-Label Use (23) Protocols for Public Health Research and Surveillance (58) Pharmacology and Pharmaceutics (49)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54882, first published .
The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

Authors of this article:

Yumi Kitahiro1 Author Orcid Image ;   Kazuhiro Yamamoto1 Author Orcid Image ;   Kimikazu Yakushijin2 Author Orcid Image ;   Takeshi Ioroi1 Author Orcid Image ;   Masaaki Tanda1 Author Orcid Image ;   Kotaro Itohara1 Author Orcid Image ;   Tomohiro Omura1 Author Orcid Image ;   Hironobu Minami2 Author Orcid Image ;   Ikuko Yano1 Author Orcid Image
Article Authors Cited by Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.